SUMMARY Twenty-five patients with left ventricular failure and low cardiac output received a 72 hour infusion of dobutamine (10) (11) (12) (13) (14) (15) Mg/kg/min) in order to determine the cardiovascular properties of this new inotropic agent. Left ventricular contractile performance improved significantly during the infusion as measured by systolic time intervals and echocardiographic parameters. Mean PEP/LVET decreased from 0.76 ± 0.03 to 0.58 ± 0.03 (P < 0.05). The percent change in internal dimension of the left ventricle from diastole to systole increased from 9.5 ± I to 16.8 ± 1 (P < 0.05) and Vcf increased from 0.47 ± 0.05 to 0.80 ± 0.06 circ/sec (P < 0.05). Mean cardiac output (nine patients) rose from 1.97 ± 0.15 to 3.33 ± DOBUTAMINE is a synthetic catecholamine systematically formulated and synthesized by Tuttle and Mills1 2 in an attempt to develop the ideal inotropic drug. Animal experiments2-6 demonstrated that this compound did increase ventricular contractility and cardiac output with little to no effect on heart rate and systemic blood pressure. The total systemic resistance generally decreased. Because these favorable pharmacologic properties differed from the properties of the available inotropic agents, dobutamine was tested in man.'88 The human data, based on brief infusion periods (10-30 min) in patients with and without congestive heart failure, are similar to the information obtained from the animal studies. At doses which significantly increased ventricular contractility and cardiac output, dobutamine did not significantly increase heart rate or systemic blood pressure. Additionally, the brief infusion resulted in some reduction in pre-load as measured by the pulmonary capillary wedge pressure or directly from the left ventricular end-diastolic pressure.
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This study was designed to determine the cardiovascular effects and other properties of dobutamine during a longterm continuous infusion in patients with severe left heart failure.
Methods

Patients
Twenty-five patients with severe left ventricular failure were studied. The mean age was 53 years (range 16-72 years) with 18 males and seven females. Twenty-one patients had a form of cardiomyopathy (I5 idiopathic, 2 viral, 2 hypertensive, 1 peripartum, 1 amyloid) and four patients had severe left ventricular dysfunction associated with valvular disease (3 aortic insufficiency, 1 had had aortic and mitral pros-0.50 L/min/m2 while mean pulmonary capillary wedge pressure fell from 28 ± 3 to 18 ± 2 mm Hg during the infusion period (both P < 0.05). These changes in cardiac function occurred without significant changes in heart rate, ventricular irritability, or blood pressure. Urine flow and urine sodium concentration increased during the infusion period.
The improvement of cardiac function without the simultaneous development or exacerbation of undesirable effects (tachycardia, premature ventricular contractions, increased pulmonary or systemic resistance, tachyphylaxis, etc.) makes dobutamine a highly desirable inotropic agent.
theses inserted for rheumatic valvular disease). Patients with arteriosclerotic heart disease or alcoholic cardiomyopathy were excluded from the study. The diagnoses were confirmed in 22 patients with cardiac catheterization and in one patient at autopsy. Two patients were evaluated with noninvasive data alone. All patients were categorized as functional class IV (NYHA). Mean duration of dyspnea on exertion was five years and of other signs and symptoms of congestive heart failure, four years. All patients had dyspnea at rest with a mean duration of nine months. Eighty-eight percent of the patients had peripheral edema for an average time of two years and 60% had generalized edema for a mean duration of ten months. All patients had gross cardiomegaly on chest X-ray with additional findings of pulmonary venous congestion in 72% and pleural effusion in 16%. All patients were on a digitalis preparation (daily oral digoxin dose of 0.375 mg in two patients, 0.25 mg in 13 patients, 0.125 mg in five patients and digitoxin 0.1 mg in five patients) and a diuretic (furosemide, daily oral dose range of 80 to 480 mg). The digitalis and diuretic were continued throughout the study period. Written informed consent was obtained prior to each study.
Infusion Period and Studies
The infusion period lasted 72 hours. Dobutamine was placed in solution with 5% dextrose in water and delivered intravenously with a calibrated Harvard pump. The initial infusion dose was 2.5 ,ug/kg/min. The rate of administration was increased every 30 minutes to dose levels of 5.0, 10.0, and 15.0 gg/kg/min. The maximal dose (15 g/kg/min in 20 patients; 10 .0 ,g/kg/min in five patients) was then continued for the remainder of the 72 hour period.
Determinations of urine flow, urine sodium concentration, BUN and serum creatinine, and measurements of daily weight and indirect blood pressures were obtained over 48 hours prior to the infusion period and continued during the 72 hour infusion. The ECG was monitored continuously over 48 hours pre-infusion and during the entire infusion period. The mean heart rate and frequency of PVCs/min were determined from one minute monitor recordings taken every five minutes during the increasing dose period and one out of 468 every 10 minutes during the continuous, pre-, and post infusion periods. An 4A ). The post infusion cardiac index decreased but remained above baseline (P < 0.05). The heart range changes were insignificant in this group, so the calculated stroke volume index increased during the infusion (fig. 4B ). The pulmonary capillary wedge pressure decreased significantly during the entire infusion period ( fig. 4C ). There was no significant difference between the pulmonary capillary wedge pressures at the various infusion rates. The total systemic resistance decreased significantly during the infusion by virtue of an increasing cardiac output and an unaltered systemic blood pressure ( fig. 4D) . Similarly, the total pulmonary resistance decreased significantly during the infusion. Although the pulmonary arteriolar resistance decreased, the changes were not significant.
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.30 Vcf; and C) ejection fraction. *P < 0.05. sion period. Thirty minutes after the discontinuation of dobutamine all values returned toward control, however, the % A D, Vcf, and EF remained significantly above and the PEP/LVET significantly below the pre-infusion values. The reduction in the PEP/LVET during the infusion was secondary to both shortening of the PEP ( fig. IC) and lengthening of the LVET (fig. 1D ). These reciprocal and hemodynamically complementary effects resulted in little to no change of the QS21 during the infusion ( fig. IB) . Figure 3A illustrates the heart rate changes during the study. A significant increase in heart rate was noted only during the initial segment of the 15 gg/kg/min dose and thereafter decreased to values similar to baseline. At no time during the infusion did the mean frequency of premature ventricular contractions significantly increase above baseline ( fig. 3B ). However, in one patient, the infusion was discontinued at 48 hours because of an increase in the frequency of his PVCs. The systolic and diastolic blood pressures did not change significantly during the infusion compared to baseline values ( fig. 3C ). The mean percent changes in serum BUN and creatinine per day are illustrated in figure 5A , B. During the preinfusion period the serum BUN and creatinine rose an average of 3.9%/day and 0.84%/day respectively. During the 72 hour infusion period the serum BUN dropped 9.1%/day and the creatinine fell 2.2%/day (both P < 0.05). Both the urine flow and urine sodium concentrations increased significantly during the infusion period compared to pre-infusion values ( fig. 5 C,D) . Although the daily weight loss went from a reduction of 0.9 ± 4 kg/day to a reduction of 2.6 ± 0.9 kg/day, this change did not achieve the significance of P < 0.05.
Clinical Information
Twenty of the 25 patients noted subjective improvement of symptoms (reduction of dyspnea, orthopnea, fatigue, etc.) during the infusion. The improvement of symptoms persisted to one week post-infusion in 17 patients. One patient developed nausea and vomiting during the 15 gg/kg/min dose with disappearance of these symptoms as the dose was have a wide margin of safety, as evidenced by the paucity of toxic manifestations in a population of patients with severe heart disease. In addition, the two patients who received 2 to 5 times the therapeutic dose developed symptoms and blood pressure and heart rate changes which were probably less dramatic than those which would have occurred with a similar overadministration of other catecholamine preparations, particularly isoproterenol and norepinephrine. The occurrence of nervousness and the onset of a mild tachycardia with the overadministration of dobutamine are relatively safe signals which would direct the physician to reduce the rate of administration of this drug.
The exact role of inotropic agents in the overall therapeutic schema of low cardiac output failure is less well defined than it was several years ago. The advent of vasodilator therapy has placed the inotropic group into a secondary role in many clinical settings. In clinical situations in which temporary inotropic support is necessary (e.g., postoperative states, vasodilator ineffectiveness, etc.) dobutamine appears to be the inotropic agent of choice. In this study, 17 of 25 patients (all functional class IV) maintained clinical improvement (5 functional class II, 12 functional class III) for at least one week after the infusion period was completed. The explanation for this sustained improvement is unclear, but it is of interest that at 30 minutes after the infusion was discontinued, the measurements of LV function were still significantly above control values. The left ventricular end diastolic volumes by echo did not change during the infusion. The amount of bed rest in hours/day during the infusion period did not differ from the pre-infusion period. Whatever the underlying mechanism for the continued improvement, dobutamine infusion may potentially become a therapeutic modality in the overall treatment plan of the low cardiac output states. Studies of the effect of intermittent continuous infusions of dobutamine in patients with low cardiac output states and studies comparing vasodilator therapy with intermittent dobutamine infusion merit consideration as possible next steps in the clinical investigation of this drug.
